Evidence map›Paper›PMID 40672686›Full record

ArticleACS pharmacology & translational science2025

Uptake Inhibition to Improve Bioavailability of Nanoparticle-Mediated Growth Factor Delivery to the Corneal Epithelium.

Levi N Kanu, Amit Chatterjee, Mohamed Y Mahmoud, Sushma V Mudigunda, Shweta Gupta, Vincent Yeung, Nikolay Boychev, Xinyao Hu, Amy E Ross, Joseph B Ciolino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Nanotechnology-Based Treatment for Ophthalmic Diseases.International journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Levi N KanuDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID https://orcid.org/0000-0001-6428-4696
Amit ChatterjeeDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.
Mohamed Y MahmoudDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.
Sushma V MudigundaDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.
Shweta GuptaDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.
Vincent YeungDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID https://orcid.org/0000-0002-5455-1049
Nikolay BoychevDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.ORCID https://orcid.org/0000-0003-2674-0835
Xinyao HuDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.
Amy E RossDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.
Joseph B CiolinoDepartment of Ophthalmology, Schepens Eye Research Institute of Mass Eye and Ear, Harvard Medical School, Boston, Massachusetts 02114, United States.

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Mass Eye and Ear-Vision Clinical Scientist Development ProgramK12EY016335 · NEI · MASSACHUSETTS EYE AND EAR INFIRMARY · PI Reza Dana · 2004 to 2026
$12.3M
NEI NIH HHS K12 EY016335NEI NIH HHS P30 EY003790
6 · The paper itself

Abstract

Nanoparticle (NP)-based drug delivery approaches may enhance the pharmacokinetics of protein therapies like epidermal growth factor (EGF). However, the small size that allows NPs to bypass barriers also confers rapid cellular internalization, which may lead to NP-encapsulated EGF bypassing its extracellular targets. In this study, we investigated the potential of sodium azidea nonspecific energy-dependent inhibitor of NP endocytosisto improve the functional efficacy of NP-mediated growth factor delivery. We generated NPs composed of FITC-labeled poly-(lactic-

Indexed as

cell uptakecorneadrug deliveryepidermal growth factornanoparticleswound healing

Identifiers

PMID40672686
PMCPMC12260936

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.